Schizophrenia affects approximately 24 million people worldwide with a treatment-resistant rate of 30–50%. This paper synthesises convergent evidence across genetics, neuropathology, cell biology, pharmacology, and quantum biology to support a unified upstream model centred on microtubule dysregulation. Genetic mutations in DISC1 and MAP6, postmortem neuropathological findings, live patient-derived neuron studies, and the tubulin-binding mechanism of clozapine all converge on microtubule dysfunction as the primary pathological mechanism — with dopamine and glutamate dysregulation reframed as downstream consequences. Drug-induced schizophrenia is shown to follow the same causal pathway via serotonin and cannabinoid receptor-mediated microtubule disruption. A quantum biological dimension informed by Orchestrated Objective Reduction (Orch-OR) and anaesthetic microtubule oscillation data provides a framework for schizophrenia phenomenology. Therapeutic and research implications are outlined.
Kevin Meda (2026) studied this question.